ESPE2019

Thursday 19 September 2019
07:00-20:00		REGISTRATION
08:00-10:00		ESPE Obesity Working Group (OWG) Chair(s):Tetyana Chaychenko (Kharkiv, Ukraine) test E2
08:00	WG2.1	Pathogenesis of Insulin Resistance Ram Weiss (Jerusalem, Israel)
08:24	WG2.2	EU vs. non-EU practices on Insulin Resistance assessment (ESPE ObWG project) Tetyana Chaychenko (Kharkiv, Ukraine)
08:48	WG2.3	Insulin function in obese children within the low and high ranges of impaired fasting glycemia Claude Marcus (Solna, Sweden)
09:12	WG2.4	Adolescent type 2 diabetes: Comparing prospective registries Reinhard Holl (Ulm, Germany)
09:36	WG2.5	Youth onset T2D (2018 ISPAD Consensus Guidelines) Thomas Reinehr (University of Witten/Herdecke, Datteln, Germany)
08:00-10:00		ESPE Working Group on Disorders of Sex Development (DSD) E1 Session head(s):Christa Flück (Bern, Switzerland)
08:00		Introduction Christa Flück (Bern, Switzerland)
08:05	WG1.1	Epigenetics and the androgen insensitivity syndrome PD Nadine Hornig, PhD (Kiel, Germany)
08:25	WG1.2	Oligogenic origin of DSD Nuria Camats (Barcelona, Spain)
08:45	WG1.3	Postpubertal outcome of boys born with hypospadias Lloyd Tack (Ghent, Belgium)
09:05	WG1.4	Shared or Shaped Decision-Making in DSD Jürg Streuli (Zürich, Switzerland))
09:25	WG1.5	i-dsd/i-cah
09:35	WG1.6	Endo-ERN
09:45		Discussion with attendees DSD discussion ()
09:55		Conclusion Tülay Güran (Turkey, Istanbul)
08:00-10:00		ESPE Working Group on Bone and Growth Plate (BGP) F1 Session head(s):Ciara McDonnell (Dublin, Ireland)
08:00	WG3.1	Lethal pyridoxin-independent encephalopathy in a case of perinatal hypophosphatasia Adalbert Raiman (Austria)
08:15	WG3.2	Congenital talipes equinovarus and bowing of femur due to homozygous TRPV6 mutation Saygin Abali (Turkey)
08:30	WG3.3	Mechanisms of vascular calcification and potential treatment implications Frank Rutsch (Münster, Germany)
09:05	WG3.4	Update on BOND Klaus Mohnike (Germany)
09:25	WG3.5	New insights in growth plate fusion Katherine Staines (Edinburgh, Scotland)
08:00-10:00		ESPE Working Group on Diabetes Technology (DT) F2 Session head(s):Moshe Philip (Petah Tikva, Israel)
		Introduction Moshe Phillip (Israel)
08:05	WG4.1	Impact of hypoglycemia on cognitive function Jacques Beltrand (Paris, France))
08:25	WG4.2	Impact of hyperglycemia on cognitive function Jasna Omladič (Ljubljana, Slovenia)
08:45	WG4.3	Type 2 diabetes and the brain Urakami Tatsuhiko (Tokyo, Japan)
09:05	WG4.4	Fear of hyperglycemia Michal Nevo (Petah Tikva, Israel)
09:20	WG4.5	Time in Range (TIR) - Highlights from the consensus meeting February 2019 Tadej Battelino (University of Ljublijana, Ljubljana, Slovenia)
09:40	WG4.6	How technology helps to improve TIR (open and closed loop) Boris Kovatchev (Virginia, USA)
08:00-10:00		ESPE Working Group on Paediatric and Adolescent Gynaecology (PAG) HALL B Session head(s):Anne-Simone Parent (Liège, Belgium) & Ken Ong (Cambridge, United Kingdom)
08:00	WG5.1	Early Origins of PCOS Francis Zegher (Leuven, Belgium)
08:23	WG5.2	Diagnosis & pharmacological intervention in PCOS Lourdes Ibáñez (Barcelona, Spain)
08:46	WG5.3	Lifestyle intervention in PCOS Thomas Reinehr (University of Witten/Herdecke, Datteln, Germany)
09:09	WG5.4	Androgen Excess in female athletes Angelica Hirschberg (Stockholm, Sweden)
09:32	WG5.5	Contraception in adolescence Kathy Hoeger (Rochester, USA)
08:00-10:00		ESPE Working Group on Gender Dysphoria (GD) HALL C Session head(s):Gary Butler (London, United Kingdom)
08:00	WG6.1	Assessing competence to consent to physical treatment in transgender adolescents Annelou Vries (Amsterdam, The Netherlands)
08:30	WG6.2	Surgical options for the transfemale Mark-Bram Bouman (Amsterdam, The Netherlands)
09:00	WG6.3	Surgical options for the transmale Nim Christopher (London, United Kingdom)
09:30	WG6.4	Annual General Meeting
08:00-10:00		ESPE Working Group on Turner Syndrome (TS) HALL A Session head(s):Michael Ranke (Tuebingen, Germany), Aneta Gawlik (Katowice, Poland), Malcolm Donaldson (Glasgow, United Kingdom) & Christina Kanaka-Gantenbein (Athens, Greece)
08:00		Introduction
08:05	WG7.1	Oral versus transdermal induction of puberty - The Turner Working Group of ESPE proposal Malcolm Donaldson (Glasgow, United Kingdom)
08:15	WG7.2	Theoretical and practical implications of transdermal approach to pubertal induction Berit Kristrom (Umeå, Sweden))
08:30		Discussion
08:40	WG7.3	Endocrine management of Turner Syndrome in adolescents and early adulthood Melanie Davis (London, United Kingdom)
09:05	WG7.4	Fertility preservation- technical and ethical aspects Kathrin Fleischer (Nijmegen, The Netherlands)
09:30	WG7.5	Cardiac morbidity and mortality during pregnancy in TS Anthonie Duijnhouwers (Nijmegen, The Netherlands)
09:55		Closing remarks
10:00-10:30		REFRESHMENT BREAK, POSTERS & EXHIBTION Exhibition Area
10:30-10:45		OPENING CEREMONY HALL A
10:45-11:15		PLENARY 1 - RANKL and RANK: Bone and Beyond Chair(s):Gabriele Häusler (Vienna, Austria) & Agnès Linglart (Paris, France) HALL A
	PL1	RANKL and RANK: Bone and beyond Josef Penninger (Vancouver, Canada)
11:15-11:45		ESPE AWARDS - Henning Andersen Prizes HALL A Session head(s):Mehul Dattani (London, United Kingdom)
12:00-13:30		SYMPOSIUM 1 Chair(s):Martin Wabitsch (Ulm, Germany) & Jan Lebl (Prague, Czech Republic) Novel advances in Diabetes and Obesity HALL B
	S1.1	Off the weight curve – dynamics of childhood obesity Antje Körner (Leipzig, Germany)
	S1.2	The gut microbiome and Obesity Frank Scott (Denver, USA)
	S1.3	New developments for treatments in monogenic disorders focusing on setmelanotide trials Christine Poitou (Paris, France)
12:00-13:30		SYMPOSIUM 2 Chair(s):Wolfgang Högler (Linz, Austria) & Dov Tiosano (Haifa, Israel) What’s new in bone and growth plate research. E1
	S2.1	Longitudinal bone growth: fundamental mechanisms to clinical applications Jeffrey Baron (Bethesda, USA)
	S2.2	Anabolic therapies for osteoporosis in childhood Frank Rauch (Montreal, Canada)
	S2.3	Steroid-Associated Osteoporosis in the Pediatric Population Leanne Ward (Children’s Hospital of Eastern Ontario, Ontario , Canada)
12:00-13:30		SYMPOSIUM 3 Chair(s):Olaf Hiort (Lubeck, Germany) & Laura Audi (Barcelona, Spain) Novel insights in our understanding of Disorders of Sex Development: From Genes to Clinical Outcomes HALL A
	S3.1	Genetics of DSD – do we understand it? Anu Bashamboo (Paris, France)
	S3.2	Outcomes in DSD – insight from the DSD life study Anna Nordenström (Karolinska University Hospital, Stockholm, Sweden)
	S3.3	Novel insights into sex determination Andy Greenfield (Oxford, United Kingdom)
12:00-13:30		SYMPOSIUM 4 Chair(s):Zdeněk Šumník (Prague, Czech Republic) & Thomas Danne (Hanover, Germany) ISPAD/ESPE Symposium - Complications of Type 1 Diabetes HALL C
	S4.1	Hypoglycemia in children with T1D: Past, Present, and Future David Maahs (Stanford, USA)
	S4.2	Novel advances in diabetic retinopathy screening and management Kim Donaghue (Sydney, Australia)
	S4.3	Prediction of renal and cardiovascular complications Loredana Marcovecchio (Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK)
12:00-13:30		ESPE ACTIVITIES E2
	ACT1	eLearning RLC portal
	ACT2	Science Committee activities
	ACT3	Education and training activities
13:30-14:45		LUNCH, POSTERS & EXHIBITION Exhibition Area
13:45-14:45		Industry Sponsored Satellite Symposia
14:45-15:45		MEET THE EXPERT 1.1 Holistic approach to the individual with DSD HALL B
	MTE1.1	Holistic approach to the individual with DSD Martine Cools (Ghent, Belgium)
14:45-15:45		MEET THE EXPERT 2.1 The interpretation of abnormal thyroid function tests in children and adolescents HALL C
	MTE2.1	The interpretation of abnormal thyroid function tests in children and adolescents Carla Moran (Beacon Hospital and University College Dublin, Dublin, Ireland)
14:45-16:15		HOW DO I... Chair(s):John Gregory (Cardiff, United Kingdom) HOW DO I... SESSION 1 HALL A
14:45	HDI1.1	How Do I... Manage subclinical hypothyroidism Mariacarolina Salerno (Naples, Italy)
15:15	HDI1.2	How Do I... Manage a patient with Prader Willi and GH at transition - do they benefit as adults? Maithé Tauber (Toulouse, France)
15:45	HDI1.3	How do I... Manage a child with insulin resistance Francesco Chiarelli (Chieti, Italy)
14:45-16:15		FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1 Chair(s):Elisabeth Steichen-Gersdorf (Innsbruck, Austria) & Dirk Schnabel (Berlin, Germany) E2
14:45	RFC2.1	Burosumab resulted in better clinical outcomes than continuation with conventional therapy in both younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia Wolfgang Högler (Linz, Austria)
14:50	RFC2.2	Does the treatment with recombinant human growth hormone improve final height in patients affected by X-linked hypophosphatemia? Julia André (Le Kremlin Bicêtre, France)
14:55	RFC2.3	Growth hormone effects on metacarpal bone geometry and bone age in growth hormone-deficient children David Martin (Tübingen, Germany)
15:00	RFC2.4	Bone mass and fracture prevalence in childhood brain cancer survivors 2, 5 or 7 years after off therapy Natascia di Iorgi (Genova, Italy)
15:05	RFC2.5	Long term effects of treatment with oxandrolone (Ox) in addition to growth hormone (GH) in girls with Turner syndrome (TS) on bone mineral density in adulthood Theo Sas (Rotterdam, The Netherlands)
15:10	RFC2.6	Impact of pubertal suppression on body composition and bone mineral density in adolescents with gender dysphoria Andreas Kyriakou (Glasgow, United Kingdom)
15:15	FC2.1	Continued improvement in clinical outcomes with burosumab, a fully human anti-FGF23 monoclonal antibody: results from a 3-year, phase 2, clinical trial in children with X-linked hypophosphatemia (XLH) Agnès Linglart, MD, PhD (Paris, France)
15:25	FC2.2	Benefits of long-term burosumab persist in 11 girls with X-linked hypophosphatemia (XLH) who transitioned into adolescence during the phase 2 CL201 trial Annemieke Boot (The Netherlands)
15:35	FC2.3	Higher dose of burosumab is needed for treatment of children with severe forms of X linked hypophosphatemia Volha Zhukouskaya (Le Kremlin-Bicêtre, France)
15:45	FC2.4	New imaging approaches to the quantification of musculoskeletal alterations in X-linked hypophosphatemic rickets (XLH) Adalbert Raimann (Vienna, Austria)
15:55	FC2.5	Age and gender-specific reference data for high-resolution magnetic resonance based musculoskeletal parameters in healthy children and young people Huda Elsharkasi (Glasgow, United Kingdom)
16:05	FC2.6	Validation of a new version of BoneXpert bone age in children with congenital adrenal hyperplasia (CAH), precocious puberty (PP), growth hormone deficiency (GHD), Turner syndrome (TS), and other short stature diagnoses David Martin (Tübingen, Germany)
14:45-16:15		FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders Chair(s):Leena Patel (Manchester, United Kingdom) & Senthil Senniappan (LIverpool, UK) F1
14:45	RFC3.1	European Registries For Rare Endocrine Conditions (EuRRECa): results from the pilot phase of The Platform For e-Reporting Of Rare Endocrine Conditions (e-REC) Salma Ali (Glasgow, United Kingdom)
14:50	RFC3.2	Factors affecting loss to follow-up for patients with chronic endocrine conditions during the pediatric period: a cohort study at a reference center for rare diseases Laura Atger-Lallier (Paris, France)
14:55	RFC3.3	The founder homozygous NR5A1 gene mutation p.R103Q causes asplenia and severe XY-DSD and XX-DSD in a Palestinian cohort Maha Abdulhadi-Atwan (Hebron, Palestine)
15:00	RFC3.4	Peripheral glucocorticoid metabolism may reflect resolution of inflammation in Kawasaki disease Shuji Sai (Sapporo, Japan)
15:05	RFC3.5	Evaluation of endothelial function in childhood standard risk acute lymphoblastic leukemia survivors: role of subclinical markers and identification of preventable factors Patrizia Bruzzi (Modena, Italy)
15:10	RFC3.6	Prevalence of endocrine complications in Duchenne muscular dystrophy Primož Kotnik (Ljubljana, Slovenia)
15:15	FC3.1	Germline-derived gain-of-function variants of Gsα-coding GNAS gene identified in nephrogenic syndrome of inappropriate antidiuresis: the first report Maki Fukami (Tokyo, Japan)
15:25	FC3.2	CFTR loss-of-function has effects on microRNAs (miRNAs) that regulate genes involved in growth, glucose metabolism and in fertility in in vitro models of cystic fibrosis Francesca Cirillo (Reggio Emilia, Italy)
15:35	FC3.3	Variability in drug metabolizing cytochrome P450 activities caused by human genetic variations in NADPH cytochrome P450 oxidoreductase (POR) Maria Velazquez (Bern, Switzerland)
15:45	FC3.4	Droplet digital PCR is a useful method for detection of mosaic mutations in patients with McCune–Albright syndrome Satoshi Watanabe (Nagasaki, Japan)
15:55	FC3.5	Evaluation of endocrine late effects in survivors of childhood allogeneic hematopoietic stem cell transplantation in Australia database from 1985 to 2011 Samantha Lee (Melbourne, Australia)
16:05	FC3.6	Severe infections contribute to increased risk of early death in patients with apeced Joonatan Borchers (Helsinki, Finland)
14:45-16:15		FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1 Chair(s):Sabine Hofer (Innsbruck, Austria) & Reinhard Holl (Ulm, Germany) E1
14:45	RFC1.1	Low prevalence of maternal microchimerism in Japanese children with type 1 diabetes Kikumi Ushijima (Tokyo, Japan)
14:50	RFC1.2	Gabra5 contributes to sexual dimorphism in POMC neural activity and glucose metabolism Zhou Pei (Shanghai, China)
14:55	RFC1.3	The association between IGF-1 levels and nonalcoholic fatty liver disease (NAFLD) in adolescents with type 2 diabetes Jose Morales (Mexico City, Mexico)
15:00	RFC1.4	Estimation of MODY frequency and prevalent subtypes in pediatric patients by targeted NGS Luis Salamanca (Madrid, Spain)
15:05	RFC1.5	Decreased circulating levels of MOTS-c in individuals with newly diagnosed type 1 diabetes children Caiqi Du (Wuhan, China)
15:10	RFC1.6	An oral trace element supplementation has a potential beneficial effect on glucose homeostasis in transfused patients with β-thalassemia major complicated with diabetes mellitus Nancy Elbarbary (Cairo, Egypt)
15:15	FC1.1	Insulin resistance leads to mitochondrial dysfunction in hepatocyte Hong Chen (Hangzhou, China)
15:25	FC1.2	Three new genes (PTPRD, SYT9, and WSF1) related to Korean maturity-onset diabetes in the young (MODY) children decrease insulin synthesis and secretion in human pancreatic beta cells Kyung-Mi Jang (Daegu, Republic of Korea)
15:35	FC1.3	Next generation sequencing in Greek MODY patients increases diagnostic accuracy and reveals a high percentage of MODY12 cases Amalia Sertedaki (Athens, Greece)
15:45	FC1.4	ABSTRACT WITHDRAWN
15:55	FC1.5	FADES: A birth cohort to understand the mechanisms underlying accelerated onset of autoimmunity in children with Down’s syndrome Georgina Williams (Chippenham, United Kingdom)
16:05	FC1.6	A novel biochemical marker, fatty acid-binding protein 4, in diabetic ketoacidosis in children Noah Gruber (Ramat Gan, Israel)
16:15-16:30		REFRESHMENT BREAK, POSTERS AND EXHIBITION Exhibition Area
16:30-17:00		PLENARY 2 Light, Body Clocks and Sleep: Biology to New Therapeutics HALL A Session head(s):Peter Clayton (Manchester, United Kingdom) & Annette Grüters (Heidelberg, Germany)
	PL2	Light, Body Clocks and Sleep: Biology to New Therapeutics Russell Foster (Oxford, United Kingdom)
17:00-18:00		MEET THE EXPERT 3.1 Clinical Practice Guidelines for the Care of Girls and Women with Turner Syndrome: Proceedings from the 2016 Cincinnati International Turner Syndrome Meeting HALL B
	MTE3.1	Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting Claus Gravholt (Aarhus, Denmark)
17:00-18:00		MEET THE EXPERT 4.1 Klinefelter syndrome - when should testosterone be started HALL C
	MTE4.1	Klinefelter syndrome - when should testosterone be started Julia Rohayem (Münster, Germany)
17:00-18:00		YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 1 HALL A Session head(s):Wieland Kiess (Liepzig, Germany)
17:00	YB1.1	Adrenals Evangelia Charmandari (Athens, Greece)
17:12	YB1.2	Antenatal and Neonatal Endocrinology Khalid Hussain (Sidra Medicine, Doha, Qatar)
17:24	YB1.3	Bone, Growth Plate and Mineral Metabolism Ola Nilsson (Örebro University Hospital, Stockholm, Sweden)
17:36	YB1.4	Type 2 Diabetes, Metabolic Syndrome and Lipids Orit Pinhas-Hamiel (Tel Aviv, Israel)
17:48	YB1.5	Editor's Choice Ken Ong (Cambridge, United Kingdom)
17:00-18:30		FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid Chair(s):Malgorzata Wasniewska (Messina, Italy) & A. S. Paul Van-Trotsenburg (Amsterdam, The Netherlands) E2
17:00	RFC5.1	Hurthle cell carcinoma in childhood retrospective analysis of a large series Giorgia Pepe (Messina, Italy)
17:05	RFC5.2	Ultrasound features of multinodular goiter in DICER1 syndrome Marek Niedziela (Poznan, Poland)
17:10	RFC5.3	Experience of thyroid surgery in children with intraoperative neuromonitoring Alexander Anikiev (Moscow, Russian Federation)
17:15	RFC5.4	Thyroid dysfunction in patients following thymus transplantation in a tertiary centre: a 10-year experience Sommayya Aftab (London, United Kingdom)
17:20	RFC5.5	A novel mutation in the thyroglobulin gene leading to neonatal goiter and congenital hypothyroidism in an Eritrean infant Eve Stern (Ramat Gan, Israel)
17:25	RFC5.6	Complex single nucleotide polymorphisms in SEPINA 7 lead to TBG deficiency Fang Yanlan (Hangzhou, China)
17:30	FC5.1	Randomised trial of block and replace versus dose titration antithyroid drug treatment in children and adolescents with thyrotoxicosis Claire Wood (Newcastle University, Newcastle upon Tyne, UK)
17:40	FC5.2	Lower proportion of CD19+IL-10+ and CD19+CD24hiCD27+ IL-10+, but not CD1d+CD5+CD19+CD24+CD27+ IL-10+ B cells in children with autoimmune thyroid diseases Karolina Stożek (Bialystok, Poland)
17:50	FC5.3	Predominant DICER1 mutations in pediatric follicular thyroid carcinomas Young Lee (Seoul, Republic of Korea)
18:00	FC5.4	Thyroid dysgenesis: exome-wide analysis identifies rare variants in genes involved in thyroid development and cancer Stéphanie Larrivée-Vanier (Montreal, Canada)
18:10	FC5.5	Identification of TRPC4AP as a novel candidate gene causing thyroid dysgenesis Daniela Choukair (Heidelberg, Germany)
18:20	FC5.6	Homozygous loss-of-function mutation in the SLC26A7 gene coding a novel iodide transporter causes goitrous congenital hypothyroidism Atsushi Suzuki (Nagoya, Japan)
17:00-18:30		FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity Chair(s):Julie Chowen (Madrid, Spain) & Moshe Philip (Petah Tikva, Israel) E1
17:00	RFC4.1	Expression of miRNAs in circulating exosomes derived from patients with NAFLD Junfen Fu (Zhejiang, China)
17:05	RFC4.2	Circulating exosomal miRNAs in children’s nonalcoholic steatohepatitis and the correlation with serum transaminase and uric acid Xuelian Zhou (Hangzhou, China)
17:10	RFC4.3	Dysregulated gene expression profile in visceral adipose tissue of juvenile Wistar rats with catch-up growth: association with fat expansion and metabolic parameters Judit Bassols (Salt, Spain)
17:15	RFC4.4	The novel phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib effectively inhibits growth of PTEN haploinsufficient lipoma cells Anna Kirstein (Leipzig, Germany)
17:20	RFC4.5	GDF5 increased white adipose tissue thermogenesis through p38 MAPK signaling pathway in fatty acid-binding protein 4-GDF5 transgenic mice Feihong Luo (Shanghai, China)
17:25	RFC4.6	Appetite suppressing effects of glucoregulatory peptides devoid of nausea Christian Roth (Seattle, USA)
17:30	FC4.1	Involvement of visfatin in adipose tissue fibrosis through modulation of extracellular matrix proteins Mitra Nourbakhsh (Tehran, Iran)
17:40	FC4.2	Characterization of the adipose progenitor cell marker MSCA1 in normal weight and obese children Martha Hanschkow (Leipzig, Germany)
17:50	FC4.3	Circulating growth-and-differentiation factor-15 in early life: relation to prenatal and postnatal size Marta Díaz (Barcelona, Spain)
18:00	FC4.4	The rs72613567:TA variant in the hydroxysteroid 17-beta dehydrogenase 13 gene reduces liver damage in obese children Anna Sessa (Naples, Italy)
18:10	FC4.5	Leptin gene methylation status in Egyptian infants Omneya Omar (Alexandria, Egypt)
18:30	FC4.6	Brain satiety responses to a meal in children before and after weight management intervention Christian Roth (Seattle, USA)
18:30-20:00		Industry-Sponsored Satellite Symposia
20:00-21:30		Informal ESPE Networking Event
Friday 20 September 2019
07:30-19:30		REGISTRATION
08:30-09:30		MEET THE EXPERT 5.1 Managing endocrinopathies in McCune-Albright Syndrome E1
	MTE5.1	Managing endocrinopathies in McCune-Albright Syndrome Daniele Tessaris (Torino, Italy)
08:30-09:30		MEET THE EXPERT 6.1 Management of Diabetic Ketoacidosis HALL B
	MTE6.1	Management of Diabetic Ketoacidosis Zdenek Sumnik (Prague, Czech Republic)
08:30-09:30		MEET THE EXPERT 7.1 Management of Graves disease E2
	MTE7.1	Management of Graves disease
08:30-09:30		MEET THE EXPERT 8.1 Management of neonatal hypoglycaemia HALL C
	MTE8.1	Management of neonatal hypoglycaemia Klaus Monicke (Magdeburg, Germany)
08:30-09:30		MEET THE EXPERT 1.2 Holistic approach to the individual with DSD F1
	MTE1.2	Holistic approach to the individual with DSD Martine Cools (Ghent, Belgium)
08:30-09:30		YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 2 Chair(s):Feyza Darendeliler (Istanbul, Turkey) HALL A
08:30	YB2.1	DSD and gender dysphoria Christa Flück (Bern, Switzerland)
08:42	YB2.2	Growth and Growth Factors Danilo Fintini (Rome, Italy)
08:54	YB2.3	Obesity and Weight Regulation Professor Martin Wabitsch (University of Ulm, Germany)
09:06	YB2.4	Oncology and Chronic Disease Carla Bizzarri (Rome, Italy)
09:18	YB2.5	Global Health for the Paediatric Endocrinologist Jean-Pierre Chanoine (Vancouver, Canada)
09:30-11:00		FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 6 - Bone, growth plate and mineral metabolism Session 2 Chair(s):Poonam Dhamaraj (Liverpool, United Kingdom) & Ola Nilsson (Stockholm, Sweden) HALL B
09:30	RFC6.1	EFTUD2 gene deficiency disturbs maturation of osteoblast and inhibits chondrocyte differentiation via activated p53 signaling Jing Wu (Shanghai, China)
09:35	RFC6.2	High levels of LIGHT/TNFSF14 in Prader–Willi syndrome Maria Faienza (Bari, Italy)
09:40	RFC6.3	Increased burden of common risk alleles in children with a significant fracture history Despoina Manousaki (Montreal, Canada)
09:45	RFC6.4	Targeted molecular genetic diagnosis by next generation sequence analysis method and investigation of responsible candidate genes in patients with osteogenesis imperfecta Aysun Ata (Izmir, Turkey)
09:50	RFC6.5	Evaluating genotype–phenotype correlation using an in vitro mutagenesis model in bi-allelic mutations resulting in extreme hypophosphatasia clinical phenotypes Suma Uday ()
09:55	RFC6.6	Genetic aetiology predicts growth hormone (GH) treatment outcomes in children born small-for-gestational-age with persistent short stature (SGA-SS). Lessons from a single-centre cohort Jan Lebl (Prague, Czech Republic)
10:00	FC6.1	Bone tissue characterization of a mouse model of atypical type VI osteogenesis imperfecta reveals hypermineralization of the bone matrix, elevated osteocyte lacunar density and altered vascularity Ghazal Hedjazi (Vienna, Austria)
10:10	FC6.2	Zone wise cell separation methods comparison, based on relative expression of specific growth plate markers in a pig model Alireza Javanmardi (Vienna, Austria)
10:20	FC6.3	Decreased trabecular bone mineral density and muscle area at the forearm despite improvement in glycaemic control over 3 years after simultaneous pancreas kidney transplantation Ondrej Soucek (Prague, Czech Republic)
10:30	FC6.4	Metabolically unhealthy obese children and adolescents have higher bone mineral density than normal weighted controls but lower than metabolically healthy obeses: no effect of FGF21 levels Elif Ozsu (Ankara, Turkey)
10:40	FC6.5	No change in bone density during 6 months off GH in adolescents with severe GHD at near-adult height Roland Schweizer (Tübingen, Germany)
10:50	FC6.6	Craniosynostosis in inactivating PTH/PTHrP signaling disorder 2: a non-classical feature to consider Isolina Riaño-Galan (Oviedo, Spain)
09:30-11:00		FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 7 - Diabetes and Insulin Session 2 Chair(s):Birgit Rami-Merhar (Vienna, Austria) & Ram Weiss (Jerusalem, Israel) HALL C
09:30	RFC7.1	Accuracy of glucose sensor estimate of HbA1c in children with type 1 diabetes Sarah Ehtisham (Dubai, UAE)
09:35	RFC7.2	β-cell function and glucose effectiveness in the development of impaired fasting glucose in obese European children and adolescents Christian Denzer (Ulm, Germany)
09:40	RFC7.3	Osteopontin as an early urinary marker of diabetic nephropathy in adolescents with type 1 diabetes mellitus Amany Ibrahim (Cairo, Egypt)
09:45	RFC7.4	Handgrip strength correlates with insulin resistance and the metabolic syndrome in children and adolescents: analysis of the Korean National Health and Nutrition Examination Survey 2014-2016 Hae Jung (Seoul, Republic of Korea)
09:50	RFC7.5	Dual diagnosis of type 1 diabetes and ADHD Kineret Mazor-Aronovitch (Ramat Gan, Israel)
09:55	RFC7.6	Health-related quality of life and diabetes control in immigrant and Italian children and adolescents with type 1 diabetes and in their parents Barbara Predieri (Modena, Italy)
10:00	FC7.1	Deployment of a predictive model based on CpG methylation haplotypes analysis on the insulin gene promoter, in a cohort of children and adolescents with type 1 diabetes Eleni Kotanidou (Thessaloniki, Greece)
10:10	FC7.2	Copeptin kinetics and its relationship to osmolality during rehydration for diabetic ketoacidosis in children: an observational study Gabor Szinnai (Basel, Switzerland)
10:20	FC7.3	ABSTRACT WITHDRAWN
10:30	FC7.4	Metabolic syndrome features in pre-pubertal children born after maternal pre-eclampsia Valentina Chiavaroli (The University of Auckland, Auckland, New Zealand)
10:40	FC7.5	Is the 1-hour post-load glucose level by 75g oral glucose tolerance test a new risk factor in predicting atherosclerosis? Suna Kılınç (Istanbul, Turkey)
10:50	FC7.6	2017 American Academy of Pediatrics Clinical Practice Guideline: impact on prevalence of arterial hypertension in children and adolescents with type 1 diabetes mellitus Axel Dost (Jena, Germany)
09:30-11:00		FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 8 - Pituitary, neuroendocrinology and puberty Session 1 Chair(s):Evelien Gevers (London, United Kingdom) & Juliane Léger (Paris, France) E1
09:30	RFC8.1	Trade-off between olfactory bulb and eyeball volume in precocious puberty Murat Karaoglan (Gaziantep, Turkey)
09:35	RFC8.2	Investigation of imprinting alterations in MKRN3 and DLK1 in a cohort of girls with central precocious puberty through specific DNA methylation analysis Ana Canton (São Paulo, Brazil)
09:40	RFC8.3	Central precocious puberty caused by novel mutations in the promoter and 5′-UTR region of the imprinted MKRN3 gene Pavlos Fanis (Nicosia, Cyprus)
09:45	RFC8.4	Evaluation of puberty in patients with Noonan syndrome and mutations in the RAS/MAPK genes Alexsandra Malaquias (São Paulo, Brazil)
09:50	RFC8.5	CHD7 mutations in patients with anosmic or normosmic idiopathic hypogonadotropic hypogonadism Leman Kotan (Adana, Turkey)
09:55	RFC8.6	Growth, pubertal course and long-term outcome of 46,XY boys born with atypical genitalia and low birthweight Lloyd Tack (Ghent, Belgium)
10:00	FC8.1	Hypothalamic AgRP neurons drive endurance in food-restricted mice Maria Consolata Miletta (New Haven, USA)
10:10	FC8.2	Analysis of hypothalamic metabolic circuits after normalization of body weight in mice that had been obese due to high fat diet intake Santiago Guerra-Cantera (Madrid, Spain)
10:20	FC8.3	Absence of central adrenal insufficiency in adults with Prader-Willi syndrome Anna Rosenberg (Rotterdam, The Netherlands)
10:30	FC8.4	Peripheral and hypothalamic alterations in the insulin like growth factor IGF system in response to high fat diet induced weight gain Santiago Guerra-Cantera (Madrid, Spain)
10:40	FC8.5	LGR4-Wnt β-catenin signalling directs GnRH network development, with defects leading to self-limited delayed puberty Alessandra Mancini (London, United Kingdom)
10:50	FC8.6	Source and changes in serum level of kisspeptin in female rats at different developmental stages Ahreum Kwon (Seoul, Republic of Korea)
09:30-11:00		FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 9 - Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) Chair(s):Pratik Shah (London, United Kingdom) & Jacques Beltrand (Paris, France) E2
09:30	RFC9.1	Targeted next-generation sequencing for congenital hypothyroidism with positive neonatal TSH screening results Takeshi Yamaguchi (Shimotsuke, Japan)
09:35	RFC9.2	Age-specific reference values for plasma FT4 and TSH concentrations in healthy, term neonates at day three to seven, and 13 to 15 of life J Naafs (Amsterdam, The Netherlands)
09:40	RFC9.3	Neonatal screening for congenital hypothyroidism analysis of a large cohort of affected patients 1987 2017 and relationship with perfluoroalkylated substances PFAs in north eastern Italy Rossella Gaudino (Verona, Italy)
09:45	RFC9.4	Correlation between genotype and phenotype characteristics in children with congenital hyperinsulinism (CHI) in a specialist centre Laura Bosch (London, United Kingdom)
09:50	RFC9.5	Spectrum of neuro-developmental disorders in children with congenital hyperinsulinism due to activating mutations in GLUD1 Sommayya Aftab (London, United Kingdom)
09:55	RFC9.6	Extra uterine growth restriction (EUGR) in very low birth weight infants: growth recovery and neurodevelopment by the corrected age of 2 years old Laura Lucaccioni (Modena, Italy)
10:00	FC9.1	Using CRISPR/Cas9 gene editing to study the molecular mechanisms of congenital hyperinsulinism (CHI) Preetha Purushothaman (London, UK)
10:10	FC9.2	Heterozygous insulin receptor (INSR) mutation associated with neonatal hyperinsulinaemic hypoglycaemia and familial diabetes mellitus Aashish Sethi (Liverpool, United Kingdom)
10:20	FC9.3	DNA methylation signatures in placenta and umbilical cord: association with maternal obesity Judit Bassols (Salt, Spain)
10:30	FC9.4	Prenatal environment and genetic background influence urinary steroid excretion in monozygotic twins with intra-twin birth-weight differences Sandra Schulte (Bonn, Germany)
10:40	FC9.5	Iodine status of pregnant women and their newborns in the UK – the MABY study Malcolm Donaldson (Glasgow, United Kingdom)
10:50	FC9.6	[18F]F-DOPA-PET/MRI or /CT in children with congenital hyperinsulinism Susann Empting (Magdeburg, Germany)
09:30-11:00		FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 10 - Sex differentiation, gonads and gynaecology or sex endocrinology Chair(s):Ken McElreavey (Paris, France) & Anna Nordenström (Stockholm, Sweden) F1
09:30	RFC10.1	Contemporary surgical approach in CAH 46XX – results from the I-DSD/I-CAH registries Doris Hebenstreit (Vienna, Austria)
09:35	RFC10.2	Cryptorchid boys with abrogated mini-puberty display differentially expressed genes involved in sudden infant death syndrome Faruk Hadziselimovic (Liestal, Switzerland)
09:40	RFC10.3	Level of uncertainty in diagnostic evaluation of boys with XY disorders of sex development (DSD) Malika Alimussina (Glasgow, UK)
09:45	RFC10.4	qPCR screening for Xp21.2 copy number variations in patients with elusive aetiology of 46,XY DSD Jakob Meinel (Lübeck, Germany)
09:50	RFC10.5	Variants in NWD1 gene leading to different degrees of gonadal dysgenesis Odile Gaisl (Zurich, Switzerland)
09:55	RFC10.6	A mutation in the nucleoporin-107 gene causes aberrant Dpp/BMP signaling and XX gonadal dysgenesis Tikva Shore (Jerusalem, Israel)
10:00	FC10.1	Investigating the roles of androgens in male reproductive development, maintenance and function by characterisation of androgen and cortisol deficient 11ß-hydroxylase mutant zebrafish lines James Oakes (Sheffield, United Kingdom)
10:10	FC10.2	The fruit fly, Drosophila melanogaster, as a model to elucidate human differences of sex development (DSD) Ivan Mercadé (Fribourg, Switzerland)
10:20	FC10.3	Mutations in the DEAH-box RNA helicase DHX37 are a frequent cause of 46,XY gonadal dysgenesis and 46,XY testicular regression syndrome Ken McElreavey (Paris, France)
10:30	FC10.4	Loss-of-function and missense mutations in MYRF are a novel cause of autosomal dominant 46,XY Leydig cell hypoplasia and 46,XY gonadal dysgenesis Ken McElreavey (Paris, France)
10:40	FC10.5	Transcriptome analysis of novel Sertoli cell models to highlight potential genes involved in DSD mechanism of disease Daniel Gutiérrez (Fribourg, Switzerland)
10:50	FC10.6	Evaluation of basal and GnRH stimulated AMH levels in central precocious puberty peripheral precocious puberty and premature thelarche Nursel Sahin (Ankara, Turkey)
09:30-11:00		ERN SESSION Chair(s):Anita Hokken-Koelega (Rotterdam, The Netherlands) & Peter Clayton (Manchester, United Kingdom) F2
09:30	ERN1.1	Progress in ENDO-ERN
09:45	ERN1.1	The Lifelong management of Childhood Craniopharyngioma Hermann Müller (Oldenburg, Germany)
10:15	ERN1.2	ePAG Representitive Arlene Smyth (Glasgow, United Kingdom)
10:30	ERN1.3	Thyroid Signalling Defects Edward Visser (Erasmus Medical Center, Rotterdam, The Netherlands)
11:00-11:30		REFRESHMENT BREAK, POSTERS & EXHIBITION Exhibition Area
11:30-12:00		ESPE AWARDS - Andrea Prader Prize HALL A Session head(s):Peter Clayton (Manchester, United Kingdom)
12:00-12:30		PLENARY 3 Chair(s):Nils Krone (Sheffield, United Kingdom) & Keiichi Ozono (Osaka, Japan) Glucocorticoid rhythms, stress response and the brain from neonates to adults HALL A
	PL3	Glucocorticoid rhythms, stress response and the brain from neonates to adults Stafford Lightman (Bristol, United Kingdom)
12:30-13:00		ESPE AWARDS HALL A
		ESPE Hormone Research in Paediatrics Prizes - Supported by S. Karger AG Faisal Ahmed (Glasgow, United Kingdom)
		IFCAH - ESPE Award - Supported by the International Fund Research on Congenital Adrenal Hyperplasia Michel Polak (Paris, France)
		ESPE International Outstanding Clinician Award Evangelia Charmandari (Athens, Greece)
		Outstanding Clinician Award Evangelia Charmandari (Athens, Greece)
13:00-14:30		LUNCH, POSTERS & EXHIBITION Exhibition Area
13:15-14:15		Industry-Sponsored Satellite Symposia
14:00-16:00		Global Pediatric Endocrinology and Diabetes (GPED) - The Long Winding Road towards Sustainable Access to Affordable Insulin Chair(s):Reiko Horikawa (Japan) & Ganesh Jevalikar (India) F1
14:00		Introduction Jean-Pierre Chanoine (Vancouver, Canada)
14:05		Why are we failing to address the issue of access to insulin in low- and middle- income countries? A global perspective David Beran (Geneva, Switzerland)
14:35		Insulin access: from the model list of essential medicines to the patient: new WHO initiatives Nicola Magrini (Geneva, Switzerland)
15:05		Access to insulin in China: barriers and opportunities Xiaoping Luo (Hubei, China)
15:35		Round table: how to be a leader on insulin access in your country?
14:30-16:00		CONTROVERSY Does obesity need tertiary care provision? HALL A Session head(s):Evangelia Charmandari (Athens, Greece)
	CON1.1	PRO: Does obesity need tertiary care provision? Billy White (London, United Kingdom)
	CON1.2	CON: Does obesity need tertiary care provision? Wieland Kiess (Hospital for Children and Adolescence, University of Leipzig, Leipzig, Germany)
14:30-16:00		SYMPOSIUM 5 Chair(s):Andrew Dauber (Washington, USA) & Irène Netchine (Paris, France) Impact of genomics on growth E1
	S5.1	Novel insights into genetic disorders of growth Jesús Argente (Madrid, Spain)
	S5.2	SHOX: From Basic Research to Complex Models and Therapy Gudrun ARappold (Heidelberg, Germany)
	S5.3	The role of KCNQ1in pituitary development Taneli Raivio (Helsinki, Finland)
14:30-16:00		SYMPOSIUM 6 Chair(s):Sabine Hannema (Leiden, The Netherlands) & Gary Butler (London, United Kingdom) Endocrinology meets diversity: Transgender Youth HALL B
	S6.1	Impact of cross-gender hormone treatment on structural brain networks Leo Silberbauer (Vienna, Austria)
	S6.2	Psychiatric comorbidities in Transgender Youth Annelou Vries (Amsterdam, The Netherlands)
	S6.3	Gynecological aspects and fertility issues in transgender adolescents Mick van Trotsenburg (St. Pölten, Austria)
14:30-16:00		SYMPOSIUM 7 - New Horizens in the Management in Adrenal Insufficiency Chair(s):Christa Flück (Bern, Switzerland) & Walter Bonfig (Grieskirchen, Austria) HALL C
	S7.1	Novel interventions to treat adrenal insufficiency Leonardo Guasti (London, United Kingdom)
	S7.2	Novel insights into the pathophysiology of adrenal insufficiency syndromes John Achermann (London, United Kingdom)
	S7.3	Widening the horizon - Clinical relevance of steroid hormone pathways Stefan Wudy (Justus-Liebig-Universität Gießen, Giessen, Germany)
14:30-16:30		ESPE Nursing and Allied Health Working Group (PENS) F2 Session head(s):Christine Derycke (Brussels, Belgium)
14:30	WG8.1	New topics in Turner Syndrome Siska Verlinde (Brussels, Belgium)
14:50		Discussion
14:55	WG8.2	Care and Follow up of girls with Turner Syndrome in Northern Sweden
15:15		Discussion
15:20	WG8.3	What’s New in CAH?
15:40		Discussion
15:45	WG8.4	Gynaecologic nursing care for CAH Louise Williams (London, United Kingdom)
16:05		Discussion
16:10	WG8.5	Patient perspectives on CAH Grace Summer (Leeds, United Kingdom)
16:00-16:30		PLENARY 4 Chair(s):Anders Juul (Copenhagen, Denmark) & Luca Persani (Milan, Italy) HPG -Nutrition and the hypothalamo-pituitary-gonadal axis HALL A
	PL4	HPG -Nutrition and the hypothalamo-pituitary-gonadal axis Manuel Tena-Sempere (University of Córdoba, Córdoba, Spain)
16:30-16:45		REFRESHMENT BREAK, POSTERS & EXHIBITION Exhibition Area
16:45-18:15		Industry-Sponsored Satellite Symposia
17:00-18:00		NOVEL ADVANCES 1 Chair(s):Nicolas de Roux (Paris, France) Stem cell reprogramming, IPS cells HALL B
	NA1	Single Cell technologies Karine Rizzoti (London, UK)
18:15-19:30		ESPE ANNUAL BUSINESS MEETING F2
Saturday 21 September 2019
07:30-18:30		REGISTRATION
08:00-09:00		MEET THE EXPERT 2.2 The Interpretation of Abnormal Thyroid Function Tests in Children and Adolescents E1
	MTE2.2	The interpretation of abnormal thyroid function tests in children and adolescents Carla Moran (Beacon Hospital and University College Dublin, Dublin, Ireland)
08:00-09:00		MEET THE EXPERT 3.2 Clinical Practice Guidelines for the Care of Girls and Women with Turner Syndrome: Proceedings from the 2016 Cincinnati International Turner Syndrome Meeting HALL B
	MTE3.2	Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Claus Gravholt (Aarhus, Denmark)
08:00-09:00		MEET THE EXPERT 4.2 Klinefelter syndrome - when should testosterone be started E2
	MTE4.2	Klinefelter syndrome - when should testosterone be started Julia Rohayem (Münster, Germany)
08:00-09:00		MEET THE EXPERT 5.2 Managing endocrinopathies in McCune-Albright Syndrome HALL C
	MTE5.2	Managing endocrinopathies in McCune-Albright Syndrome Daniele Tessaris (Torino, Italy)
08:00-09:00		YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 3 HALL A
08:00	YB3.1	Pituitary and Neuroendocrinology Nicolas de Roux (Paris, France)
08:12	YB3.2	Puberty Anne-Simone Parent (Liège, Belgium)
08:24	YB3.3	Thyroid Gabor Szinnai (Basel, Switzerland)
08:36	YB3.4	Type 1 Diabetes Wieland Kiess (Hospital for Children and Adolescence, University of Leipzig, Leipzig, Germany)
08:48	YB3.5	The Year in Science & Medicine Ze'ev Hochberg (Haifa, Isreal))
09:00-10:30		HOW DO I... Chair(s):Marco Cappa (Rome, Italy) HOW DO I...SESSION 2 HALL A
09:00	HDI2.1	How do I…. Manage micropenis in a child? Silvano Bertelloni (Pisa, Italy)
09:30	HDI2.2	How Do I... Diagnosing growth hormone resistance? Marie-José Walenkamp (Amsterdam, The Netherlands)
10:00	HDI2.3	How Do I... Manage of an asymptomatic child with T1D and transglutaminase positivity? Elke Frohlich-Reiterer (Graz, Austria)
09:00-10:30		FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 11 - Pituitary, neuroendocrinology and metabolism Session 2 Chair(s):Gerhard Binder (Tübingen, Germany) & Katharina Main (Copenhagen, Denmark) HALL B
09:00	RFC11.1	National United Kingdom evidence- and consensus-based guidelines for the investigation, treatment and long-term follow-up of paediatric craniopharyngioma Hoong-Wei Gan (Great Ormond Street Hospital, London, UK)
09:05	RFC11.2	Prevalence and predicting factors of endocrine dysfunction in children with NF1 and optic gliomas Anna Grandone (Naples, Italy)
09:10	RFC11.3	Polycystic ovarian syndrome in adolescents: utilising discovery proteomics and the search to identify novel non-invasive biomarkers Harriet Gunn (London, UK)
09:15	RFC11.4	Increased adrenal and testicular androgen concentrations before puberty and in early puberty correlate to adult height outcomes in males with Silver–Russell syndrome Kjersti Kvernebo-Sunnergren (Gothenburg, Sweden)
09:20	RFC11.5	IGF-1 serum concentrations and growth in children with congenital leptin deficiency (CLD) before and after replacement therapy with metreleptin Marianna Beghini (Ulm, Germany)
09:25	RFC11.6	Final height reduction in transgender adolescent girls: a case series Ilse Hellinga (Amsterdam, The Netherlands)
09:30	FC11.1	Phenotypic characterization of a large pediatric cohort of patients with genetic forms of congenital hypopituitarism Cecilia Cionna (London, United Kingdom)
09:40	FC11.2	A novel minor spliceosome defect associated with growth hormone deficiency GHD and primary ovarian insufficiency POI Leyla Akin (Kayseri, Turkey)
09:50	FC11.3	A novel genetic aetiology for familial neonatal central diabetes insipidus Eran Lavi (Jerusalem, Israel)
10:00	FC11.4	Whole exome sequencing in a familial case of adamantinomatous craniopharyngioma revealed two hits affecting Wnt-signaling pathway Anatoly Tiulpakov (Moscow, Russian Federation)
10:10	FC11.5	Survival, endocrine disorders and quality of life in 135 children with craniopharyngioma after surgical or combined treatment Nadia Mazerkina (Moscow, Russian Federation)
10:20	FC11.6	Pubertal timing in parents is associated with timing of pubertal milestones in offspring of concordant sex – but only inconsistently with milestones in offspring of discordant sex Alexander Busch (Copenhagen, Denmark)
09:00-10:30		FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 12 - Growth and syndromes (to include Turner syndrome) Chair(s):Sandro Loche (Cagliari, Italy) & Helen Storr (London, United Kingdom) HALL C
09:00	RFC12.1	Karyotyping of oocytes, granulosa cells and stromal cells in the ovarian tissue from patients with Turner syndrome: a pilot study Sapthami Nadesapillai (Nijmegen, The Netherlands)
09:05	RFC12.2	Treatment with growth hormone increases Klotho concentration in patients with Turner syndrome Beata Wikiera (Wroclaw, Poland)
09:10	RFC12.3	Imprinting defects and copy number variations in short children born small for gestational age Masayo Kagami (Tokyo, Japan)
09:15	RFC12.4	NIPBL is required for postnatal growth and neural development Xiaohui Wu (Hangzhou, China)
09:20	RFC12.5	Cognitive and neuroradiological assessments in Silver Russell patients Giuseppa Patti (Genova, Italy)
09:25	RFC12.6	Exploring the usefulness of a new type of pubertal height reference based on growth aligned or onset of pubertal growth Anton Holmgren (Gothenburg, Sweden)
09:30	FC12.1	Increasing knowledge in IGF1R defects: lessons from 20 new patients. Eloïse Giabicani (Paris, France)
09:40	FC12.2	NPR2 gene mutations were found in 5.4% children with familial short stature Lukas Plachy (Prague, Czech Republic)
09:50	FC12.3	Growth hormone treatment in adults with Prader–Willi syndrome has sustained positive effects on body composition Layla Damen (Rotterdam, The Netherlands)
10:00	FC12.4	Integration of transcriptomic and epigenomic data in childhood identifies a subset of individuals born small for gestational age (SGA) with “catch-up” growth who become pre-hypertensive in early adulthood Terence Garner (Manchester, United Kingdom)
10:10	FC12.5	Integrated analysis of baseline blood transcriptome and genome identifies clusters of Turner syndrome patients with different responses to recombinant human growth hormone Adam Stevens (Manchester, United Kingdom)
10:20	FC12.6	An integrated systems biology analysis of the genome, epigenome and transcriptome identifies a distinct pattern of hypermethylation associated with low childhood growth Terence Garner (Manchester, United Kingdom)
09:00-10:30		FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 13 - Adrenals and HP axis Chair(s):Stefan Wudy (Gießen, Germany) & Angela Huebner (Dresden, Germany) E1
09:00	RFC13.1	Children and adolescents in the United States with congenital adrenal hyperplasia are not at increased risk for attention-deficit/hyperactivity disorder Lauren Harasymiw (Minneapolis, USA)
09:05	RFC13.2	Development of novel non-invasive strategies for monitoring of treatment control in patients with congenital adrenal hyperplasia Irina-Alexandra Bacila (Sheffield)
09:10	RFC13.3	Establishment of reference intervals for hair cortisol in healthy children aged 0-18 years using mass spectrometric analysis Ineke Kruijff (Nieuwegein, The Netherlands)
09:15	RFC13.4	Loss-of-function NNT mutations impair antioxidants mechanisms and decreases cortisol secretion in patients with familial glucocorticoid deficiency Aline Bodoni (Ribeirao Preto, Brazil)
09:20	RFC13.5	Genetics of familial glucocorticoid deficiency over the decades: phenotypic variability and associated features C Smith (London, United Kingdom)
09:25	RFC13.6	Inhibitory effects of curcuminoids on the enzymes from the steroidogenic pathway Patricia Castaño (Bern, Switzerland)
09:30	FC13.1	Peptide MC2R antagonists as a new potential therapeutic approach for congenital adrenal hyperplasia Angela Huebner (Dresden, Germany)
09:40	FC13.2	Sexual dimorphism in cortisol production and metabolism throughout pubertal development: a longitudinal study Britt Keulen (Amsterdam, The Netherlands)
09:50	FC13.3	YAP1-HIPPO pathway as a novel prognostic marker and therapeutic target for pediatric patients with adrenocortical tumors (ACT) Candy More (São Paulo, Brazil)
10:00	FC13.4	Biphasic glucocorticoid rhythm in one-month old infants: reflection of a developing HPA-axis? Jonneke Hollanders (Amsterdam, The Netherlands)
10:10	FC13.5	SGPL1 deficiency leads to downregulation of key enzymes within the steroidogenic pathway Avinaash Maharaj (London)
10:20	FC13.6	Insights into the role of cortisol in the formation of the Clock/Bmal1 complex and its interaction with dsDNA, via molecular dynamics simulations Nicolas Nicolaides (Athens, Greece)
09:00-10:30		FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 14 - GH and IGF1 Chair(s):Ivo Arnhold (Sao Paulo, Brazil) & Joachim Woelfle (Erlangen, Germany) E2
09:00	RFC14.1	Papp-a2 deficiency results in sex-dependent modifications in hypothalamic regulation of energy homeostasis Jesús Argente (Madrid, Spain)
09:05	RFC14.2	Deciphering genetic aetiology among children born small-for-gestational-age with persistent short stature (SGA-SS): phenotypic characteristics at diagnosis in a large single-centre cohort Ledjona Toni (Prague, Czech Republic)
09:10	RFC14.3	MicroRNAs change and target key regulatory genes involved in longitudinal growth in patients with idiopathic isolated growth hormone deficiency (IGHD) on growth hormone (GH) treatment Maria Elisabeth Street (Parma, Italy)
09:15	RFC14.4	GHR transcript heterogeneity may explain the phenotypic variability in patients with homozygous GHR pseudoexon (6Ψ) mutation Sumana Chatterjee (Bristol, UK)
09:20	RFC14.5	Bioactive IGF-I concentration compared to total IGF-I concentration before and after 1 year of high-dose growth hormone in short children born small for gestational age – North European SGA Study (NESGAS) Rikke Jensen (Rigshospitalet , Copenhagen, Denmark)
09:25	RFC14.6	Growth hormone deficiency (GHD): assessing burden of disease in children and adolescents: the growth hormone deficiency – child impact measure (GHD-CIM) Meryl Brod (Mill Valley, USA)
09:30	FC14.1	Inhibition of IGF1R by IGF1R/IR inhibitor OSI906 as a targeted therapy for glioblastoma: in vitro & in vivo studies Ayelen Martin (Buenos Aires, Argentina)
09:40	FC14.2	Pubertal onset in 1572 girls with short, normal and tall stature: associations to height, serum IGF-I and PAPP-A2 genotypes Emmie Upners (Copenhagen, Denmark)
09:50	FC14.3	Papp-a2 deficiency induces sex-specific changes in hydroxyapatite-(CaOH) crystallinity and the effects of IGF-1 on bone composition in adult mice Jesús Argente (Madrid, Spain)
10:00	FC14.4	Once-weekly TransCon hGH vs. Daily hGH in pediatric growth hormone deficiency: the phase 3 heiGHt trial Elpis Vlachopapadopoulou (Athens, Greece)
10:10	FC14.5	Once-weekly somapacitan vs daily growth hormone (Norditropin®) in childhood growth hormone deficiency: One-year results from a randomised phase 2 trial Lars Sävendahl (Stockholm, Sweden)
10:20	FC14.6	Effects of 8 years of growth hormone treatment on cognition in children with Prader–Willi syndrome Anita Hokken-Koelega (Rotterdam, The Netherlands)
09:00-10:30		FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 15 - Late Breaking Session Chair(s):Lou Metherell (London, UK) & Yves Le-Bouc (Paris, France) F1
09:00	RFC15.1	Preclinical studies of acrodysostosis gene aav therapy in a knock in r368 x prkar1 a mouse model Catherine Stunff (Le Kremlin-Bicêtre, France)
09:05	RFC15.2	BMP4 mutations as a novel cause of normosmic hypogonadotropic hypogonadism A Topaloglu (Jackson, USA)
09:10	RFC15.3	Metformin treatment affects ACTH receptor activation and downstream signaling: a potential treatment for ACTH excess disorders and management of hyperandrogenic states Shaheena Parween (Bern, Switzerland)
09:15	RFC15.4	Clinical and genetic characterization of 148 patients with persistent or transient congenital hyperinsulinism: a population-based study in Finns Jonna Männistö (Kuopio, Finland)
09:20	RFC15.5	De novo missense mutation in SP7 in a patient with cranial hyperostosis, long bone fragility, and increased osteoblast number Adalbert Raimann (Vienna, Austria)
09:25	RFC15.6	Absence of puberty and estrogen resistance by estrogen alpha receptor inactivation in two sisters: a mutation for variable phenotypic severity Clémence Delcour (Paris, France)
09:30	FC15.1	DLG2 mutations in patients with delayed or absent puberty Youn Jee (Bethesda, USA)
09:40	FC15.2	HDAC4 mutations cause diabetes and induce β-cell FoxO1 nuclear exclusion Klemens Raile (Berlin, Germany)
09:50	FC15.3	The P450 side-chain cleavage isozyme cyp11a2 facilitates interrenal and gonadal steroid hormone biosynthesis in developing and adult zebrafish James Oakes (Sheffield, United Kingdom)
10:00	FC15.4	Defects in the GnRH neuroendocrine network affect the timing of puberty Tansit Saengkaew (London, United Kingdom)
10:10	FC15.5	Effects of Bifidobacterium animalis subsp. lactis on children with Prader–Willi syndrome: a randomized, double-blind, placebo-controlled, crossover trial Marta Ramon-Krauel (Barcelona, Spain)
10:20	FC15.6	Leptin influences the down-regulation of UCP-1 expression in brown adipose tissue during negative energy balance Vicente Barrios (Madrid, Spain)
10:30-11:00		REFRESHMENT BREAK, POSTERS & EXHIBITION Exhibition Area
11:00-11:30		PLENARY 5 Chair(s):Stefan Riedl (Vienna, Austria) & Faisal Ahmed (Glasgow, United Kingdom) How to reduce waste and increase value in translational biomedical research HALL A
	PL5	How to reduce waste and increase value in translational biomedical research Ulrich Dirnagl (Berlin, Germany)
11:30-12:00		ESPE AWARDS ESPE Research Award HALL A Session head(s):Agnès Linglart (Paris, France)
12:00-12:30		PLENARY 6 Chair(s):Mehul T. Dattani (London, United Kingdom) & Rasa Verkauskiene (Kaunas, Lithuania) Pituitary Gigantism - an update HALL A
	PL6	Pituitary Gigantism - an update Albert Beckers (Liège, Belgium)
12:30-14:00		LUNCH, POSTERS & EXHIBITION Exhibition Area
12:45-13:45		Industry Sponsored Satellite Symposia
14:00-15:00		YOUNG INVESTIGATORS SESSION F1 Session head(s):Faisal Ahmed (Glasgow, United Kingdom)
	YI1.1	In search for novel monitoring tools to detect chronic over- or under-treatment in children with CAH Erica van den Akker (Rotterdam, The Netherlands)
	YI1.2	The role of the gut microbiome in metabolism Valentina Chiavaroli (The University of Auckland, Auckland, New Zealand)
		ESPE Young Investigator Awards
14:00-15:00		MEET THE EXPERT 6.2 Management of Diabetic Ketoacidosis HALL B
	MTE6.2	Management of Diabetic Ketoacidosis Zdenek Sumnik (Prague, Czech Republic)
14:00-15:00		MEET THE EXPERT 7.2 Management of Graves disease E2
	MTE7.2	Management of Graves disease Tim Cheetham (Newcastle, UK)
14:00-15:00		MEET THE EXPERT 8.2 Management of neonatal hypoglycaemia HALL C
	MTE8.2	Management of neonatal hypoglycaemia Klaus Monicke (Magdeburg, Germany)
14:00-15:00		NOVEL ADVANCES 2 Genetic imprinting analysis in clinical practice E1
	NA2	Genetic imprinting analysis in clinical practice Deborah Mackay (Southampton, United Kingdom)
15:00-15:30		REFRESHMENT BREAK, POSTERS & EXHIBITION Exhibition Area
15:30-17:00		SYMPOSIUM 8 Chair(s):Elke Froehlich-Reiterer (Graz, Austria) & Loredana Marcovecchio (Cambridge, United Kingdom) Autoimmunity: From diagnosis to treatment E1
15:30	S8.1	New autoantibodies in endocrine autoimmunity development: Lessons from APECED Pärt Peterson (Tartu, Estonia)
16:00	S8.2	Novel monogenic forms of autoimmune diabetes Sarah Flanagan (Exeter, UK)
16:30	S8.3	Bone marrow transplant for genetically determined autoimmunity Mary Slatter (London, United Kingdom)
15:30-17:00		SYMPOSIUM 9 Chair(s):Stepanka Pruhova (Prague, Czech Republic) & Francesco Chiarelli (Chieti, Italy) Heterogeneity of paediatric diabetes HALL B
	S9.1	Diversity in monogenic diabetes management and prognosis Pål Njølstad (Bergen, Norway)
	S9.2	Diagnostic and therapeutic implications of double diabetes Tatsuhiko Urakami (Tokyo, Japan)
	S9.3	Obesity and T2 diabetes: How to find a population at risk Silva Arslanian (Pittsburgh, USA)
15:30-17:00		SYMPOSIUM 10 Chair(s):Cheri Deal (Montreal, Canada) Brain development and sex: Is it chromosomes or hormones? E2
	S10.1	Multifaceted origins of sex differences in the brain Erin Reinl (Maryland, USA)
	S10.2	The pubertal brain Anne-Lise Goddings (London, United Kingdom)
	S10.3	How hormones impact on emotion and cognition --- new insights from Magnetic resonance imaging Sven Müller (Ghent, Belgium)
15:30-17:00		SYMPOSIUM 11 Chair(s):Leo Dunkel (London, United Kingdom) & Mohamad Maghnie (Genoa, Italy) Recent advances in our understanding of Hypogonadotrophic hypogonadism HALL C
	S11.1	Novel insights into the molecular basis of hypogonadotrophic hypogonadism Ravikumar Balasubramanian (Boston, USA)
	S11.2	Novel insights into the regulation of reproduction from 3D imaging of the GnRH and kisspeptin neuronal populations Paolo Giacobini (Milan, Italy)
	S11.3	Novel insights into the role of semaphorin signalling in GnRH neuron development and failure Anna Cariboni (Milan, Italy)
17:00-17:30		ESPE AWARDS HALL A
		ESPE International Award Peter Clayton (Manchester, United Kingdom)
		ESPE President Poster Awards Gabriele Häusler (Vienna, Austria))
17:30-18:00		PLENARY 7 Chair(s):Asma Deeb (Abu Dhabi, UAE) & Tadej Battelino (Ljubljana, Slovenia) Novel advances in artificial pancreas development HALL A
	PL7	Novel advances in artificial pancreas development Boris Kovatchev (Virginia, USA)
18:00-18:15		ESPE 2019 CLOSING CEREMONY HALL A
19:00-00:00		THE ESPE EVENING THE CITY HALL

ESPE2019

Thursday 19 September 2019

Friday 20 September 2019

Saturday 21 September 2019